Page namespace (page_namespace ) | 0 |
Page title without namespace (page_title ) | 'Nicotine patch' |
Full page title (page_prefixedtitle ) | 'Nicotine patch' |
Old page wikitext, before the edit (old_wikitext ) | '{{Cleanup|date=July 2009}}
[[Image:Nicoderm.JPG||thumb|right|A 21 mg dose [[Nicoderm]] CQ patch applied to the left arm]]
A '''nicotine patch''' is a [[transdermal patch]] that releases [[nicotine]] into the body through the skin. It is used as an aid in [[nicotine replacement therapy]] (NRT), a process for [[smoking cessation]]. The first published study of the pharmacokinetics of a transdermal nicotine patch in humans was authored by Jed E. Rose, Ph.D., Murray E. Jarvik, M.D., Ph.D. and K. Daniel Rose, M.D., in the journal Drug and Alcohol Dependence (vol. 13, pp.209-213, 1984). This was followed by publication of results of a study of smokers showing that a transdermal nicotine patch reduced craving for cigarettes (Rose JE, Herskovic JE, Trilling Y and Jarvik ME, Clinical Pharmacology and Therapeutics, vol. 38, pp. 450-456, 1985). Dr. Frank T. Etscorn III, filed a patent on January the 23rd 1985 and was issued the patent on July 1, 1986 (U.S. Patent #4,597,961). The University of California filed a competing patent application nearly 3 years after Dr. Etscorn's filing on February the 19th, 1988, which was granted on May 1st 1990 (U.S. Patent #4,920,989).
==Issues==
===Efficacy===
Dozens of clinical trials have shown that the patch approximately doubles success rates over placebo treatment. Placebo tests show a 5.9% success rate, in comparison to the 7.2% blind active tests, and the 10.8% open tests.<ref>http://healthpsych.psy.vanderbilt.edu/health-patch.htm</ref><ref>Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Quick Reference Guide for Clinicians. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. April 2009</ref>
==Alternate uses==
Nicotine patches are under study to help relieve the symptoms of [[post-surgical pain]].<ref>[http://www.medicalnewstoday.com/articles/85508.php Nicotine Patch Decreases Post Surgical Pain]</ref>
Studies are being conducted about the use of transdermal nicotine patches to treat anxiety, depression, and inattentiveness in subjects with [[ADHD]].<ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446482/ Transdermal Nicotine in Adult ADHD With Depression and Anxiety ]</ref>
==See also==
* [[Murray Jarvik]]
* [[Smoking cessation]]
* [[Nicotine replacement therapy]]
* [[Nicotine lozenge]]
* [[Nicotine gum]]
* [[Transdermal patch]]
* [[Nicoderm CQ]]
==References==
<references />
{{Dosage forms|state=show}}
{{Routes of administration}}
{{DEFAULTSORT:Nicotine Patch}}
[[Category:Smoking cessation]]
[[Category:Transdermal patches]]
[[de:Nikotinpflaster]]
[[es:Parche de nicotina]]
[[nl:Nicotinepleister]]' |
New page wikitext, after the edit (new_wikitext ) | '{{Cleanup|date=July 2009}}
[[Image:Nicoderm.JPG||thumb|right|A 21 mg dose [[Nicoderm]] CQ patch applied to the left arm]]
A '''nicotine patch''' is a [[transdermal patch]] that releases [[nicotine]] into the body through the skin. It is used as an aid in [[nicotine replacement therapy]] (NRT), a process for [[smoking cessation]]. The first published study of the pharmacokinetics of a transdermal nicotine patch in humans was authored by Jed E. Rose, Ph.D., Murray E. Jarvik, M.D., Ph.D. and K. Daniel Rose, M.D., in the journal Drug and Alcohol Dependence (vol. 13, pp.209-213, 1984). This was followed by publication of results of a study of smokers showing that a transdermal nicotine patch reduced craving for cigarettes (Rose JE, Herskovic JE, Trilling Y and Jarvik ME, Clinical Pharmacology and Therapeutics, vol. 38, pp. 450-456, 1985). Dr. Frank T. Etscorn III, filed a patent on January the 23rd 1985 and was issued the patent on July 1, 1986 (U.S. Patent #4,597,961). The University of California filed a competing patent application nearly 3 years after Dr. Etscorn's filing on February the 19th, 1988, which was granted on May 1st 1990 (U.S. Patent #4,920,989).
==Issues==
===Efficacy===
Dozens of clinical trials have shown that the patch approximately doubles success rates over placebo treatment. Placebo tests show a 5.9% success rate, in comparison to the 7.2% blind active tests, and the 10.8% open tests.<ref>http://healthpsych.psy.vanderbilt.edu/health-patch.htm</ref><ref>Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Quick Reference Guide for Clinicians. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. April 2009</ref>
'''''STAY DENCH'''''
==Alternate uses==
Nicotine patches are under study to help relieve the symptoms of [[post-surgical pain]].<ref>[http://www.medicalnewstoday.com/articles/85508.php Nicotine Patch Decreases Post Surgical Pain]</ref>
Studies are being conducted about the use of transdermal nicotine patches to treat anxiety, depression, and inattentiveness in subjects with [[ADHD]].<ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446482/ Transdermal Nicotine in Adult ADHD With Depression and Anxiety ]</ref>
==See also==
* [[Murray Jarvik]]
* [[Smoking cessation]]
* [[Nicotine replacement therapy]]
* [[Nicotine lozenge]]
* [[Nicotine gum]]
* [[Transdermal patch]]
* [[Nicoderm CQ]]
==References==
<references />
{{Dosage forms|state=show}}
{{Routes of administration}}
{{DEFAULTSORT:Nicotine Patch}}
[[Category:Smoking cessation]]
[[Category:Transdermal patches]]
[[de:Nikotinpflaster]]
[[es:Parche de nicotina]]
[[nl:Nicotinepleister]]' |